By Oliver Griffin 
 

GlaxoSmithKline PLC (GSK.LN) said Friday that headline results from its DREAMM-2 study for treatment of multiple myeloma, a type of blood cancer, were positive.

The pharmaceutical company said the two-arm study of its treatment belantamab mafodotin met its primary objective and demonstrated a clinically meaningful overall response rate.

Safety and tolerability was consistent with that observed in the DREAMM-1 study, GlaxoSmithKline said.

Data from the DREAMM-2 study will be the basis for regulatory filings starting later this year, the company said. Belantamab mafodotin is on track for regulatory submission by the end of 2019, it said.

 

Write to Oliver Griffin at oliver.griffin@dowjones.com; @OliGGriffin

 

(END) Dow Jones Newswires

August 23, 2019 02:28 ET (06:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.